TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02577783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone
Description: doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAD regimen: bortizomib, dexamethasone and doxorubicin
Description: doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
Study: NCT04430725

Intervention type: PROCEDURE
Intervention: Wedge Excision
Description: Undergo wedge resection
Study: NCT05959187

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pharmacogenomic testing
Description: Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
Study: NCT03125447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speed and accuracy answer to visual stimuli
Description: A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: speed and accuracy answer to visual stimuli
Description: A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
Study: NCT04211935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of PCA
Description: A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of ESB for postoperative pain control after MIRPE
Description: Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of INC for postoperative pain control after MIRPE
Description: Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
Study: NCT02889107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personal frequency modulated systems
Description: patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
Study: NCT04001062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Fixation
Description: For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Operative Management
Description: 1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union
Study: NCT04884841

Intervention type: OTHER
Intervention: Patients diagnosed with postoperative complications
Description: Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)

Intervention type: OTHER
Intervention: Patients without postoperative complications
Description: Patients without postoperative complications
Study: NCT02851654

Intervention type: DEVICE
Intervention: Infrared oculography
Description: The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
Study: NCT02896725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keratin dressings
Description: Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care dressings
Description: Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
Study: NCT04385407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Simeprevir + Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Simeprevir + Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Simeprevir + Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Simeprevir + Ribavirin
Study: NCT04432220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation group(Apixaban group)
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Study: NCT04299087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No application of rTMS
Study: NCT02761525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver nanoparticles
Description: Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
Study: NCT00767260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM-MNC+HOT
Description: Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM-MNC
Description: Autologous Bone Marrow Mononuclear cell Infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOT
Description: Hyperbaric Oxygen Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMT
Description: hypoglycemic drugs or exogenous insulin
Study: NCT01836601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered nighttime communication bundle
Study: NCT03312855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revacept 80 mg
Description: single dose, intravenous application of 80 mg Revacept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revacept 160 mg
Description: single dose, intravenous application of 180 mg Revacept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, intravenous application of Placebo solution
Study: NCT05751005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides vs. Placebo
Description: Participants were randomized into one of three treatment groups.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides vs. Placebo
Description: Participants were randomized into one of three treatment groups.
Study: NCT01695369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A; Comfilcon A
Description: Senofilcon A; Comfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A; Comfilcon A
Description: Senofilcon A; Comfilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A; Senofilcon A
Description: Comfilcon A; Senofilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A; Senofilcon A
Description: Comfilcon A; Senofilcon A
Study: NCT02574299

Intervention type: OTHER
Group type: OTHER
Intervention: E-learning
Description: Management of auditory processing disorders with serious game (E-learning)

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aids fitting
Description: Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
Study: NCT00955110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: 15mg or 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: 15mg or 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: 30mg or 60mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: 30mg or 60mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a sugar pill.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 8 mg
Study: NCT02040246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
Study: NCT03120910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse CO-Oximeter Sensor
Description: Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
Study: NCT00639067

Intervention type: DEVICE
Intervention: Breath Collection Apparatus
Description: Breath collected and analyzed for markers of lung cancer.

Intervention type: DEVICE
Intervention: Breath Collection Apparatus
Description: Breath collected and analyzed for markers of lung cancer.

Intervention type: DEVICE
Intervention: Breath Collection Apparatus
Description: Breath collected and analyzed for markers of lung cancer.

Intervention type: DEVICE
Intervention: Breath Collection Apparatus
Description: Breath collected and analyzed for markers of lung cancer.
Study: NCT00003270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: High energy X-rays
Study: NCT04415138

Intervention type: DEVICE
Intervention: Robotic-assisted mitral valve repair
Description: Mitral valve repair using robotic technology (DaVinci X platform)
Study: NCT00609271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet
Description: \<40 grams carbohydrate/day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low fat diet
Description: \<30% fat, \<7% saturated fat
Study: NCT02916862

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Corn Fiber (SCF) without Calcium
Description: Participants will consume a supplement with 12 g/day of SCF for 12 months

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Soluble Corn Fiber (SCF) + Calcium
Description: Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume a supplement without SCF or calcium carbonate for 12 months

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + calcium
Description: Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
Study: NCT02551640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeatForward App (on study smartphone)
Description: The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group.
Study: NCT03396939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis
Description: All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
Study: NCT02947945

Intervention type: DRUG
Group type: OTHER
Intervention: Reslizumab
Description: All subjects will receive Reslizumab
Study: NCT00582387

Intervention type: GENETIC
Intervention: specimen samples
Description: blood, urine and tissue

Intervention type: BEHAVIORAL
Intervention: questionnaires
Study: NCT03195595

Intervention type: DEVICE
Intervention: mitral valve replacement
Description: early postoperative outcome regarding pain in minimal invasive technique

Intervention type: DEVICE
Intervention: conventional mitral valve replacement
Description: early postoperative outcome regarding pain in conventional median sternotomy
Study: NCT01839994

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CF-CRT combined with BT or SBRT boost.
Description: CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
Study: NCT04366960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin
Study: NCT01679327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Study: NCT01839994

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CF-CRT alone
Description: Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal treatment (neoadjuvant androgen deprivation)
Description: Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (neoadjuvant androgen deprivation)
Description: Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
Study: NCT02864875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Receive fibrinogen concentrate 50mg/kg of body weight after randomization
Study: NCT03945331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: DS8R Electrical Stimulator For Human Research

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: DS8R Electrical Stimulator For Human Research
Study: NCT01679327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate (CF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT05488158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulation
Description: Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
Study: NCT03945331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulation system
Description: Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
Study: NCT02062177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
Study: NCT03721653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg iv over 30 minutes day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg iv over 30 minutes day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 165 mg/sqm iv over 60 minutes day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/sqm iv over 60 minutes day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 3200 mg/sqm 48 h-continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 3200 mg/sqm 48 h-continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
Study: NCT04037722

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey + 20 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 45 g whey + 20 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB + Whey
Description: 50 g ketone + 45 g whey + 20 g maltodextrin
Study: NCT00081653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 3 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 100mg po monthly for 3 years
Study: NCT04516915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 twice daily at 22.5mg doses for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir twice daily at 75mg doses for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir twice daily at 75mg doses for 14 days
Study: NCT04432753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lung Cancer Screening Decision Aid with Incidental Findings Information
Description: The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung Cancer Screening Decision Aid without Incidental Findings Information
Description: The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
Study: NCT03013530

Intervention type: PROCEDURE
Intervention: Decision making for ICU patients' care
Description: Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
Study: NCT04651036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0605
Description: a pegfilgrastim biosimilar to US Neulasta.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US Neulasta
Description: US Neulasta